Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Hearing Disorders: HELP
Articles by Sheila Pritchard
Based on 1 article published since 2010
(Why 1 article?)
||||

Between 2010 and 2020, Sheila Pritchard wrote the following article about Hearing Disorders.
 
+ Citations + Abstracts
1 Review Clinical Practice Recommendations for the Management and Prevention of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers. 2016

Lee, Jong W / Pussegoda, Kusala / Rassekh, Shahrad R / Monzon, Jose G / Liu, Geoffrey / Hwang, Soomi / Bhavsar, Amit P / Pritchard, Sheila / Ross, Colin J / Amstutz, Ursula / Carleton, Bruce C / Anonymous7720860. ·*Center for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada; †Pharmaceutical Outcomes Programme, British Columbia Children's Hospital, Vancouver, British Columbia, Canada; ‡Child and Family Research Institute, Vancouver, British Columbia, Canada; §Department of Pediatrics, Division of Pediatric Hematology/Oncology/Bone Marrow Transplant, British Columbia Children's Hospital, Vancouver, British Columbia, Canada; ¶Department of Medical Oncology, Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada; ‖Department of Medical Oncology, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; **Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada; ††Division of Translational Therapeutics, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada; and ‡‡Institute of Clinical Chemistry, Inselspital Bern University Hospital, University of Bern, Bern, Switzerland. ·Ther Drug Monit · Pubmed #26960170.

ABSTRACT: Currently no pharmacogenomics-based criteria exist to guide clinicians in identifying individuals who are at risk of hearing loss from cisplatin-based chemotherapy. This review summarizes findings from pharmacogenomic studies that report genetic polymorphisms associated with cisplatin-induced hearing loss and aims to (1) provide up-to-date information on new developments in the field, (2) provide recommendations for the use of pharmacogenetic testing in the prevention, assessment, and management of cisplatin-induced hearing loss in children and adults, and (3) identify knowledge gaps to direct and prioritize future research. These practice recommendations for pharmacogenetic testing in the context of cisplatin-induced hearing loss reflect a review and evaluation of recent literature, and are designed to assist clinicians in providing optimal clinical care for patients receiving cisplatin-based chemotherapy.